Press coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 48.2045132011591 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Separately, BidaskClub downgraded Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 7th.

Shares of Sinovac Biotech (SVA) opened at $8.55 on Friday. Sinovac Biotech has a twelve month low of $4.60 and a twelve month high of $8.67. The firm has a market capitalization of $471.55, a price-to-earnings ratio of -853.65 and a beta of 0.19.

COPYRIGHT VIOLATION NOTICE: “Sinovac Biotech (SVA) Earning Somewhat Positive Media Coverage, Analysis Shows” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Insider Buying and Selling by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with's FREE daily email newsletter.